GeoVax's GEO-CM04S1 Shows Superior Immune Response in CLL Patients Compared to mRNA Vaccines

GeoVax Labs, Inc. has unveiled promising clinical data at the 2025 European Hematology Association Hybrid Congress, showcasing the efficacy of its GEO-CM04S1 vaccine in chronic lymphocytic leukemia (CLL) patients. The study, presented by Dr. Alexey V. Danilov, compared the immune responses elicited by GEO-CM04S1, a multi-antigen vaccine, against those of an authorized mRNA-based COVID-19 vaccine in a Phase 2 trial. Findings revealed that GEO-CM04S1 significantly enhanced T cell responses, including IFN-γ secretion and activation-induced markers, surpassing the mRNA vaccine's performance in this immunocompromised population.

The implications of these results are profound, as CLL patients often exhibit diminished responses to conventional vaccines due to their underlying immune dysfunction. GEO-CM04S1's ability to elicit robust cellular and humoral immune responses, including SARS-CoV-2 Nucleocapsid-specific IgG and T cell responses, positions it as a potentially critical tool in addressing the unmet needs of immunocompromised individuals. With the mRNA vaccine failing to meet the primary immunogenicity endpoint, the trial has shifted to exclusively enroll participants in the GEO-CM04S1 arm, underscoring the vaccine's promising profile.

Dr. Kelly T. McKee, Jr., GeoVax's Chief Medical Officer, emphasized the clinical and immunologic advantages of the company's multi-antigen approach, particularly for patients with hematologic malignancies. The safety profile of both vaccines was favorable, with no severe adverse events reported, further supporting GEO-CM04S1's potential as a safer, more effective option for vulnerable populations. As GeoVax continues to evaluate GEO-CM04S1 in ongoing Phase 2 trials, these findings could herald a new era in vaccine development, offering hope for enhanced protection against COVID-19 and other infectious diseases for those most at risk.